EPS: As of FY2025 Q1, the actual value is USD -1.61.<h3>Segment Revenue</h3><ul><li>The company operates primarily in the Therapeutics segment, focusing on the development of innovative treatments for CNS disorders and other diseases, including RASopathies and certain cancers.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended March 31, 2025, the net loss was $3,563,238, compared to $3,860,840 for the same period in 2024, representing a decrease of 7.7%.</li><li>Loss from Operations: The loss from operations for the three months ended March 31, 2025 was $3,680,179, compared to $4,040,774 for the same period in 2024, a decrease of 8.9%.</li><li>General and Administrative Expenses: These expenses decreased by approximately $341,000, or 14.9%, for the three months ended March 31, 2025 compared to the same period in 2024.</li><li>Research and Development Expenses: These expenses decreased by approximately $19,000, or 1.1%, for the three months ended March 31, 2025 compared to the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the three months ended March 31, 2025, net cash used in operating activities was $3,055,757, compared to $4,321,085 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the three months ended March 31, 2025, net cash provided by financing activities was $1,474,306.</li></ul><h3>Unique Metrics</h3><ul><li>Stock-Based Compensation: Total stock-based compensation related to the company’s stock options was $96,985 for the three months ended March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to advance PAS-004 into a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1-associated plexiform neurofibromas, followed by pediatric patients, and ultimately complete registrational clinical trials in these patient populations.</li><li>Non-Core Business: The company has two programs in the discovery stage, addressing limitations in the treatment paradigm for ALS (PAS-003) and schizophrenia (PAS-001).</li><li>Priority: The company expects research and development expenses to increase in fiscal year 2025 due to clinical research for PAS-004 and manufacturing costs related to drug supply for clinical trials.</li></ul>

PASITHEA THERAPEUTICS CORP C/WTS 12/08/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.61